July 30, 2021 - ROSEN LOGO.jpg
ROSEN, A LEADING, LONGSTANDING, AND TOP RANKED FIRM, Encourages AbbVie Inc. Investors with Losses Over $100K to Secure Counsel Before Important Deadline in Securities Class Action – ABBV
April 16, 2022 11:00 ET | The Rosen Law Firm PA
NEW YORK, April 16, 2022 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of AbbVie Inc. (NYSE: ABBV) between April 30, 2021 and...
Inventiva receives a €4 million milestone payment from AbbVie for cedirogant Phase IIb initiation
January 31, 2022 16:00 ET | INVENTIVA
Daix (France), Long Island City (New York, United States), January 31, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral...
Inventiva reçoit un paiement d'étape de 4 M€ de la part d’AbbVie suite au lancement de l’étude de Phase IIb avec cedirogant
January 31, 2022 16:00 ET | INVENTIVA
Daix (France), Long Island City (New York), Etats-Unis, le 31 janvier 2022 – Inventiva S.A. (« Inventiva » ou la « Société ») (Euronext Paris et Nasdaq : IVA), société biopharmaceutique spécialisée...
Dr. Azurii Collier
Women In Bio Elects Dr. Azurii Collier as 2022 President-Elect
December 20, 2021 11:47 ET | Women In Bio
Pittsburgh, PA, Dec. 20, 2021 (GLOBE NEWSWIRE) -- Women In Bio (WIB), a national organization of professionals committed to promoting the careers, leadership and entrepreneurship of all women in the...
IDERA_5C_RGB-01.jpg
Idera Pharmaceuticals Announces Tilsotolimod Updates
December 14, 2021 16:32 ET | Idera Pharmaceuticals, Inc.
EXTON, Pa., Dec. 14, 2021 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera,” the “Company,” “we,” “us,” and “our”) (Nasdaq: IDRA) today announced clinical updates regarding tilsotolimod, its...
Ronald McDonald House Charities (RMHC) Announces Impact of Historic Partnership with AbbVie
August 24, 2021 09:00 ET | Ronald McDonald House Charities
Chicago, Aug. 24, 2021 (GLOBE NEWSWIRE) -- Today, Ronald McDonald House Charities® (RMHC®) is grateful to announce the transformational impact of AbbVie’s $100 million contribution to the...
BES_Mark.jpg
SOLITON ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of SOLY and Encourages Investors to Contact the Firm
May 11, 2021 11:33 ET | Bragar Eagel & Squire
NEW YORK, May 11, 2021 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the board members of...
Harpoon_logo (002).jpg
Harpoon Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Update
May 06, 2021 16:04 ET | Harpoon Therapeutics
Presented encouraging data at the AACR Annual Meeting on potential therapeutic effects of TriTACs and ProTriTACs Appointed experienced biotech leader Alan Colowick, M.D., to board of directors ...
IDERA_5C_RGB-01.jpg
Idera Pharmaceuticals Announces New U.S. Patent Coverage for Tilsotolimod Through September 2037
September 28, 2020 08:45 ET | Idera Pharmaceuticals, Inc.
EXTON, Pa., Sept. 28, 2020 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today announced that the U.S. Patent and Trademark Office has issued U.S. Patent No. 10,772,907 (the ‘907...
IDERA_5C_RGB-01.jpg
Idera Pharmaceuticals to Present Tilsotolimod Data at ESMO Virtual Congress 2020
September 15, 2020 07:18 ET | Idera Pharmaceuticals, Inc.
Final data from ILLUMINATE-204 trial in advanced melanoma and final results from ILLUMINATE-101 trial in refractory solid tumors to be presentedAbbVie to present a trial-in-progress poster of ABBV-368...